| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | beta-catenin binding | 3.44e-05 | 120 | 31 | 4 | GO:0008013 | |
| GeneOntologyMolecularFunction | actin filament binding | 4.02e-04 | 227 | 31 | 4 | GO:0051015 | |
| MousePheno | retina spots | 7.61e-06 | 19 | 29 | 3 | MP:0012671 | |
| Domain | VINCULIN_1 | 1.49e-08 | 4 | 30 | 3 | PS00663 | |
| Domain | Alpha_catenin | 1.49e-08 | 4 | 30 | 3 | IPR001033 | |
| Domain | Vinculin_CS | 1.49e-08 | 4 | 30 | 3 | IPR000633 | |
| Domain | Vinculin | 3.73e-08 | 5 | 30 | 3 | PF01044 | |
| Domain | Vinculin/catenin | 1.30e-07 | 7 | 30 | 3 | IPR006077 | |
| Domain | TRPM_tetra | 1.49e-05 | 4 | 30 | 2 | PF16519 | |
| Domain | TRPM_tetra | 1.49e-05 | 4 | 30 | 2 | IPR032415 | |
| Domain | VitD_rcpt | 2.24e-04 | 14 | 30 | 2 | IPR000324 | |
| Domain | Ion_trans_dom | 7.97e-04 | 114 | 30 | 3 | IPR005821 | |
| Domain | Ion_trans | 7.97e-04 | 114 | 30 | 3 | PF00520 | |
| Domain | zf-C4 | 2.47e-03 | 46 | 30 | 2 | PF00105 | |
| Domain | NUCLEAR_REC_DBD_1 | 2.47e-03 | 46 | 30 | 2 | PS00031 | |
| Domain | Znf_hrmn_rcpt | 2.47e-03 | 46 | 30 | 2 | IPR001628 | |
| Domain | Nuclear_hrmn_rcpt | 2.47e-03 | 46 | 30 | 2 | IPR001723 | |
| Domain | ZnF_C4 | 2.47e-03 | 46 | 30 | 2 | SM00399 | |
| Domain | NUCLEAR_REC_DBD_2 | 2.47e-03 | 46 | 30 | 2 | PS51030 | |
| Domain | - | 2.58e-03 | 47 | 30 | 2 | 1.10.565.10 | |
| Domain | HOLI | 2.69e-03 | 48 | 30 | 2 | SM00430 | |
| Domain | Nucl_hrmn_rcpt_lig-bd | 2.69e-03 | 48 | 30 | 2 | IPR000536 | |
| Domain | Hormone_recep | 2.69e-03 | 48 | 30 | 2 | PF00104 | |
| Domain | - | 3.77e-03 | 57 | 30 | 2 | 3.30.50.10 | |
| Domain | Znf_NHR/GATA | 3.90e-03 | 58 | 30 | 2 | IPR013088 | |
| Domain | IQ | 5.79e-03 | 71 | 30 | 2 | PF00612 | |
| Domain | IQ | 7.47e-03 | 81 | 30 | 2 | SM00015 | |
| Domain | IQ_motif_EF-hand-BS | 9.15e-03 | 90 | 30 | 2 | IPR000048 | |
| Domain | IQ | 9.75e-03 | 93 | 30 | 2 | PS50096 | |
| Pathway | BIOCARTA_CELL2CELL_PATHWAY | 1.07e-06 | 12 | 25 | 3 | M12851 | |
| Pathway | KEGG_ENDOMETRIAL_CANCER | 1.03e-04 | 52 | 25 | 3 | M19877 | |
| Pathway | BIOCARTA_CELL2CELL_PATHWAY | 1.08e-04 | 9 | 25 | 2 | MM1366 | |
| Pathway | WP_ENDOMETRIAL_CANCER | 1.82e-04 | 63 | 25 | 3 | M39623 | |
| Pathway | KEGG_ADHERENS_JUNCTION | 2.82e-04 | 73 | 25 | 3 | M638 | |
| Pathway | WP_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY | 2.94e-04 | 74 | 25 | 3 | M39462 | |
| Pathway | KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC | 2.94e-04 | 74 | 25 | 3 | M16376 | |
| Pathway | REACTOME_MYOGENESIS | 8.14e-04 | 24 | 25 | 2 | MM15174 | |
| Pathway | KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION | 1.09e-03 | 116 | 25 | 3 | M2164 | |
| Pathway | REACTOME_TRP_CHANNELS | 1.11e-03 | 28 | 25 | 2 | MM14943 | |
| Pathway | REACTOME_TRP_CHANNELS | 1.11e-03 | 28 | 25 | 2 | M27241 | |
| Pathway | REACTOME_MYOGENESIS | 1.19e-03 | 29 | 25 | 2 | M853 | |
| Pathway | KEGG_TIGHT_JUNCTION | 1.59e-03 | 132 | 25 | 3 | M11355 | |
| Pathway | WP_NUCLEAR_RECEPTORS | 2.04e-03 | 38 | 25 | 2 | MM15865 | |
| Pathway | WP_NUCLEAR_RECEPTORS | 2.04e-03 | 38 | 25 | 2 | M39657 | |
| Pathway | KEGG_PATHWAYS_IN_CANCER | 2.39e-03 | 325 | 25 | 4 | M12868 | |
| Pubmed | Leucine zipper domain of HIV-1 gp41 interacted specifically with alpha-catenin. | 6.41e-10 | 3 | 31 | 3 | 11883950 | |
| Pubmed | The cytoplasmic domain of HIV-1 gp41 interacts with the carboxyl-terminal region of alpha-catenin. | 6.41e-10 | 3 | 31 | 3 | 10420987 | |
| Pubmed | 2.56e-09 | 4 | 31 | 3 | 18775424 | ||
| Pubmed | Adhesion protein VSIG1 is required for the proper differentiation of glandular gastric epithelia. | 2.24e-08 | 7 | 31 | 3 | 21991385 | |
| Pubmed | Functional analysis of ectodermal β-catenin during external genitalia formation. | 3.58e-08 | 8 | 31 | 3 | 23480356 | |
| Pubmed | 1.05e-07 | 11 | 31 | 3 | 14657280 | ||
| Pubmed | 7.23e-07 | 20 | 31 | 3 | 34220450 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 21278253 | ||
| Pubmed | αE-catenin is an autoinhibited molecule that coactivates vinculin. | 7.69e-07 | 2 | 31 | 2 | 22586082 | |
| Pubmed | Monomeric α-catenin links cadherin to the actin cytoskeleton. | 7.69e-07 | 2 | 31 | 2 | 23417122 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 24100690 | ||
| Pubmed | Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. | 8.44e-07 | 21 | 31 | 3 | 19129494 | |
| Pubmed | Modulation of apical constriction by Wnt signaling is required for lung epithelial shape transition. | 9.76e-07 | 22 | 31 | 3 | 27913639 | |
| Pubmed | Epidermal development requires ninein for spindle orientation and cortical microtubule organization. | 1.64e-06 | 26 | 31 | 3 | 30923192 | |
| Pubmed | The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. | 1.64e-06 | 26 | 31 | 3 | 23077317 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 23589308 | ||
| Pubmed | Structure of the dimerization and beta-catenin-binding region of alpha-catenin. | 2.31e-06 | 3 | 31 | 2 | 10882138 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 22421363 | ||
| Pubmed | α-Catenin-dependent cytoskeletal tension controls Yap activity in the heart. | 2.31e-06 | 3 | 31 | 2 | 29467248 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 9370228 | ||
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 17989230 | ||
| Pubmed | 4.61e-06 | 4 | 31 | 2 | 21708131 | ||
| Pubmed | Alpha-catenins control cardiomyocyte proliferation by regulating Yap activity. | 4.61e-06 | 4 | 31 | 2 | 25305307 | |
| Pubmed | N-cadherin mediates cortical organization in the mouse brain. | 4.61e-06 | 4 | 31 | 2 | 17222817 | |
| Pubmed | 4.61e-06 | 4 | 31 | 2 | 8174789 | ||
| Pubmed | 4.61e-06 | 4 | 31 | 2 | 22211741 | ||
| Pubmed | Chromatin Remodeling BAF155 Subunit Regulates the Genesis of Basal Progenitors in Developing Cortex. | 5.30e-06 | 38 | 31 | 3 | 30240734 | |
| Pubmed | Differential expression of alpha-E-catenin and alpha-N-catenin in the developing cerebral cortex. | 7.68e-06 | 5 | 31 | 2 | 16457793 | |
| Pubmed | 7.68e-06 | 5 | 31 | 2 | 17052462 | ||
| Pubmed | 7.68e-06 | 5 | 31 | 2 | 2349235 | ||
| Pubmed | 7.68e-06 | 5 | 31 | 2 | 16325583 | ||
| Pubmed | 7.68e-06 | 5 | 31 | 2 | 7925023 | ||
| Pubmed | 7.68e-06 | 5 | 31 | 2 | 2788574 | ||
| Pubmed | 1.15e-05 | 6 | 31 | 2 | 17113272 | ||
| Pubmed | 1.15e-05 | 6 | 31 | 2 | 12089526 | ||
| Pubmed | Cadherin-dependent adhesion is required for muscle stem cell niche anchorage and maintenance. | 1.15e-05 | 6 | 31 | 2 | 38456551 | |
| Pubmed | 1.15e-05 | 6 | 31 | 2 | 24080911 | ||
| Pubmed | Requirement for N-cadherin-catenin complex in heart development. | 1.15e-05 | 6 | 31 | 2 | 21680756 | |
| Pubmed | 1.15e-05 | 6 | 31 | 2 | 16185771 | ||
| Pubmed | 1.15e-05 | 6 | 31 | 2 | 12975353 | ||
| Pubmed | 1.61e-05 | 7 | 31 | 2 | 18397997 | ||
| Pubmed | 1.61e-05 | 7 | 31 | 2 | 12808048 | ||
| Pubmed | Expression and cell membrane localization of catenins during mouse preimplantation development. | 1.61e-05 | 7 | 31 | 2 | 8853988 | |
| Pubmed | 1.61e-05 | 7 | 31 | 2 | 17535849 | ||
| Pubmed | 1.61e-05 | 7 | 31 | 2 | 9837810 | ||
| Pubmed | The cell adhesion molecule M-cadherin is not essential for muscle development and regeneration. | 1.61e-05 | 7 | 31 | 2 | 12052883 | |
| Pubmed | 2.15e-05 | 8 | 31 | 2 | 12068957 | ||
| Pubmed | NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes. | 2.15e-05 | 8 | 31 | 2 | 21292004 | |
| Pubmed | 2.15e-05 | 8 | 31 | 2 | 7626889 | ||
| Pubmed | Switching of α-Catenin From Epithelial to Neuronal Type During Lens Epithelial Cell Differentiation. | 2.76e-05 | 9 | 31 | 2 | 28692740 | |
| Pubmed | Expression of catenins during mouse embryonic development and in adult tissues. | 2.76e-05 | 9 | 31 | 2 | 8821035 | |
| Pubmed | NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. | 2.76e-05 | 9 | 31 | 2 | 12695331 | |
| Pubmed | Lima1 mediates the pluripotency control of membrane dynamics and cellular metabolism. | 3.44e-05 | 10 | 31 | 2 | 35105859 | |
| Pubmed | 3.44e-05 | 10 | 31 | 2 | 16691566 | ||
| Pubmed | Association of a common AGO1 variant with lung cancer risk: a two-stage case-control study. | 3.44e-05 | 10 | 31 | 2 | 20721975 | |
| Pubmed | Voltage-dependent conformational changes of Kv1.3 channels activate cell proliferation. | 3.45e-05 | 208 | 31 | 4 | 33230847 | |
| Pubmed | 4.21e-05 | 11 | 31 | 2 | 24095903 | ||
| Pubmed | Lis1 is essential for cortical microtubule organization and desmosome stability in the epidermis. | 4.21e-05 | 11 | 31 | 2 | 21844209 | |
| Pubmed | 4.21e-05 | 11 | 31 | 2 | 16466397 | ||
| Pubmed | 5.05e-05 | 12 | 31 | 2 | 26929452 | ||
| Pubmed | Dynamic expression of the TRPM subgroup of ion channels in developing mouse sensory neurons. | 5.05e-05 | 12 | 31 | 2 | 19850157 | |
| Pubmed | Mechanochemical control of epidermal stem cell divisions by B-plexins. | 5.96e-05 | 13 | 31 | 2 | 33637728 | |
| Pubmed | 6.95e-05 | 14 | 31 | 2 | 19933188 | ||
| Pubmed | Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. | 9.72e-05 | 1257 | 31 | 7 | 36526897 | |
| Pubmed | 1.04e-04 | 17 | 31 | 2 | 11781569 | ||
| Pubmed | alphaE-catenin controls cerebral cortical size by regulating the hedgehog signaling pathway. | 1.30e-04 | 19 | 31 | 2 | 16543460 | |
| Pubmed | E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions. | 1.60e-04 | 21 | 31 | 2 | 15775979 | |
| Pubmed | Mapping the expression of transient receptor potential channels across murine placental development. | 2.10e-04 | 24 | 31 | 2 | 33884443 | |
| Pubmed | Close encounters: regulation of vertebrate skeletal myogenesis by cell-cell contact. | 2.10e-04 | 24 | 31 | 2 | 15923648 | |
| Pubmed | Automated yeast two-hybrid screening for nuclear receptor-interacting proteins. | 2.27e-04 | 133 | 31 | 3 | 15604093 | |
| Pubmed | 2.27e-04 | 634 | 31 | 5 | 34591612 | ||
| Pubmed | 2.28e-04 | 25 | 31 | 2 | 16382100 | ||
| Pubmed | αE-Catenin Is a Positive Regulator of Pancreatic Islet Cell Lineage Differentiation. | 2.47e-04 | 26 | 31 | 2 | 28793255 | |
| Pubmed | 2.66e-04 | 27 | 31 | 2 | 16460286 | ||
| Pubmed | 3.29e-04 | 30 | 31 | 2 | 30480076 | ||
| Pubmed | Interactome Analysis of the Nucleocapsid Protein of SARS-CoV-2 Virus. | 3.84e-04 | 159 | 31 | 3 | 34578187 | |
| Pubmed | 3.99e-04 | 33 | 31 | 2 | 23718855 | ||
| Pubmed | 3.99e-04 | 33 | 31 | 2 | 19834762 | ||
| Pubmed | The splicing regulator Rbfox2 is required for both cerebellar development and mature motor function. | 3.99e-04 | 33 | 31 | 2 | 22357600 | |
| Pubmed | 5.03e-04 | 754 | 31 | 5 | 35906200 | ||
| Pubmed | Large-scale characterization of HeLa cell nuclear phosphoproteins. | 5.67e-04 | 774 | 31 | 5 | 15302935 | |
| Pubmed | 6.17e-04 | 41 | 31 | 2 | 21052544 | ||
| Pubmed | 7.11e-04 | 44 | 31 | 2 | 19322198 | ||
| Pubmed | H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. | 8.68e-04 | 1294 | 31 | 6 | 30804502 | |
| Interaction | CDH12 interactions | 1.80e-06 | 17 | 29 | 3 | int:CDH12 | |
| Interaction | CTNNBIP1 interactions | 3.18e-05 | 43 | 29 | 3 | int:CTNNBIP1 | |
| GeneFamily | Transient receptor potential cation channels | 3.89e-04 | 28 | 19 | 2 | 249 | |
| GeneFamily | Nuclear hormone receptors | 1.19e-03 | 49 | 19 | 2 | 71 | |
| Coexpression | GSE3982_EOSINOPHIL_VS_BCELL_DN | 7.42e-05 | 198 | 30 | 4 | M5411 | |
| Coexpression | GSE7548_NAIVE_VS_DAY28_PCC_IMMUNIZATION_CD4_TCELL_UP | 7.57e-05 | 199 | 30 | 4 | M6839 | |
| Coexpression | YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_0 | 7.65e-05 | 72 | 30 | 3 | M15699 | |
| Coexpression | GSE39820_TGFBETA1_VS_TGFBETA3_IN_IL6_TREATED_CD4_TCELL_UP | 7.72e-05 | 200 | 30 | 4 | M5623 | |
| Coexpression | YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_0 | 9.71e-05 | 78 | 30 | 3 | MM867 | |
| ToppCell | COVID-19-kidney-Technical/muscle_(Imm)|kidney / Disease (COVID-19 only), tissue and cell type | 7.77e-08 | 163 | 30 | 5 | 19c28ce16a588a7f4a035c32726f6ccd67702b5b | |
| ToppCell | COVID-19-kidney-Technical/muscle_(Mes)|kidney / Disease (COVID-19 only), tissue and cell type | 3.83e-06 | 159 | 30 | 4 | 5335cbcdeaf2bbd0268bbfe0e45c8c0d288e640d | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Degenerative_Proximal_Tubule_Epithelial_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.65e-06 | 167 | 30 | 4 | 3edb0570e583bb527165bcd8a4c25a042054043b | |
| ToppCell | PBMC-Mild-cDC_9|Mild / Compartment, Disease Groups and Clusters | 6.83e-06 | 184 | 30 | 4 | 2e0c9a2c40c892a2d435eafb31f1f838de9baf15 | |
| ToppCell | mild-Myeloid-Immature_Neutrophils_2|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 8.08e-06 | 192 | 30 | 4 | 0445fdc670fa7b847dcd0a061d7736ddcf3519ba | |
| ToppCell | COVID-19-kidney-Epithelial_Doublet|kidney / Disease (COVID-19 only), tissue and cell type | 7.86e-05 | 124 | 30 | 3 | d6f59ddb9b9df02b5201f23fa5fb78f3fd891ee9 | |
| ToppCell | COVID-19-kidney-Mito-rich_Int|kidney / Disease (COVID-19 only), tissue and cell type | 8.83e-05 | 129 | 30 | 3 | 57b705106aec7bbfc587de1ccd4f2335fc44dd6f | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT1|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.04e-05 | 130 | 30 | 3 | 6434d9106ccb38786dad36fab80163dfc07b6eb7 | |
| ToppCell | facs-Marrow-B-cells-3m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.06e-04 | 137 | 30 | 3 | 4dcb15de821439011df1bb0bbd7682d674bd725d | |
| ToppCell | facs-Marrow-B-cells-3m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.06e-04 | 137 | 30 | 3 | c05ceeb7b483324604cb3f647d2da2b3786071b1 | |
| ToppCell | COVID-19-kidney-Technical/muscle_(EC)|kidney / Disease (COVID-19 only), tissue and cell type | 1.10e-04 | 139 | 30 | 3 | 64c35411bbe67acb5010dadc4b0b1be0f8b17737 | |
| ToppCell | COVID-19-Fibroblasts-Mesothelial_FB|COVID-19 / group, cell type (main and fine annotations) | 1.15e-04 | 141 | 30 | 3 | 7e6dcccb74e7ee90b69dc91b59491b84f3a713c9 | |
| ToppCell | COVID-19-kidney-Technical/muscle_(PCT)|kidney / Disease (COVID-19 only), tissue and cell type | 1.27e-04 | 146 | 30 | 3 | c55f1bdb6ac43b4118cb27ea7c879527e1afcbab | |
| ToppCell | COVID-19-kidney-Technical/muscle|kidney / Disease (COVID-19 only), tissue and cell type | 1.33e-04 | 148 | 30 | 3 | 0dbd87078f54ee1c2f8ec64e8bac9dfddb9c181e | |
| ToppCell | E16.5-samps-Mesenchymal-Matrix_fibroblast-_fetal-matrix_-_immature_3|E16.5-samps / Age Group, Lineage, Cell class and subclass | 1.35e-04 | 149 | 30 | 3 | 651494e84be03dc7b061ebdfa91756a1c507b9b4 | |
| ToppCell | LPS_only-Epithelial_alveolar-AT_1-AT2_Progenitor|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.46e-04 | 153 | 30 | 3 | e7a074ea8232bacf924be78a244a8507c7e1ebc8 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Neural-neural_cell-Schwann_Cell_/_Neural|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.70e-04 | 161 | 30 | 3 | 7d1bc73f4c82465b3f489d6737048b0cd54f22cf | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Neural-neural_cell-Schwann_Cell_/_Neural-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.70e-04 | 161 | 30 | 3 | 410eef62c83c704cbfc5a1b643c4db11bbdcd81f | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Neural|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.70e-04 | 161 | 30 | 3 | 71022485da6754a2b57b4c3e758e3de4c95cc292 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Neural-neural_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.70e-04 | 161 | 30 | 3 | 59ae8a7c9a04ecaa335b8064852a5a91a21780bd | |
| ToppCell | droplet-Lung-nan-18m-Lymphocytic-plasma_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.76e-04 | 163 | 30 | 3 | 5efecdd8a069a822bc9d35b407092925a865e629 | |
| ToppCell | droplet-Lung-nan-18m-Lymphocytic-Plasma_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.76e-04 | 163 | 30 | 3 | 0d94a427f86e62aba12c397c6d7b8cd297f3a0e5 | |
| ToppCell | droplet-Lung-18m-Hematologic-lymphocytic-plasma_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.80e-04 | 164 | 30 | 3 | b92e7c91910d518627376166c6ea9ed333b3d07e | |
| ToppCell | droplet-Lung-18m-Hematologic-lymphocytic-plasma_cell-plasma_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.80e-04 | 164 | 30 | 3 | a1e43c6b3e2553f5604100db6e92bf244b70c36d | |
| ToppCell | PND14-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_prolif|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.86e-04 | 166 | 30 | 3 | 575c325db88d6909cdf0d5e664bd9098b89d4401 | |
| ToppCell | Children_(3_yrs)-Immune-enucleated_erythrocyte-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.93e-04 | 168 | 30 | 3 | 8f0c4dfad9f6fed9dcc31795abfe77758ceb46a1 | |
| ToppCell | 3'-GW_trimst-2-LargeIntestine-Neuronal-Glial_immature-Glia_3_(BCAN+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.96e-04 | 169 | 30 | 3 | 2456b3e7776e8a2214972be1b4d66a3ca5480ae0 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid-Myeloid_monocytic-classical_monocyte-Classical_monocytes-Classical_monocytes_L.1.2.4.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.00e-04 | 170 | 30 | 3 | cf22a843ae2d9cd6693507fed2b7c6a45abea10e | |
| ToppCell | wk_08-11-Epithelial-Proximal_epithelial-basal_late|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 2.00e-04 | 170 | 30 | 3 | 83320d37f0fc74e492cfe3de18f5c499eaa9fd3e | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_low-phase|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.10e-04 | 173 | 30 | 3 | 506efcaa5afd6ed5e565c4c4def6a4505fea97c5 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.17e-04 | 175 | 30 | 3 | d52794426f2703a80e91ae0a8ff2d8e0ce4aa4a8 | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.17e-04 | 175 | 30 | 3 | 454f03e6109d65f5db08dbb41ecc19ffb6bbc4e0 | |
| ToppCell | Control-Epithelial_alveolar-AT_1-Differentiating_AT1|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.25e-04 | 177 | 30 | 3 | 9af14a056eb6d88c6f11b09f6d4c0d3448d647d5 | |
| ToppCell | ILEUM-inflamed-(9)_Enteric_neurons|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 2.29e-04 | 178 | 30 | 3 | d9142151819afb0dc22bfb32a9c9dba5f553067d | |
| ToppCell | Control-Epithelial_alveolar-AT_1|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.29e-04 | 178 | 30 | 3 | aa7d43c655df493f1330a5001efaa484e4a19f69 | |
| ToppCell | ILEUM-inflamed-(9)_Neuro_cell|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 2.29e-04 | 178 | 30 | 3 | 611504b0a9e6318b18fba83787b03f9245c82252 | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.32e-04 | 179 | 30 | 3 | 04ce3673e46606f63d9c87bcba3a64c96817d812 | |
| ToppCell | human_hepatoblastoma-Tumor_cells-T6|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 2.32e-04 | 179 | 30 | 3 | 14fc8ccb6b215063d747643f47d780d2b237eb67 | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.40e-04 | 181 | 30 | 3 | b45b11428d13950369347e051d4d517efb2bd4fd | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_1-AT1-AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.44e-04 | 182 | 30 | 3 | cc79e0cc21e2fdc4ef77f052818d27b9f707aec1 | |
| ToppCell | pdx-Tumor_cells-T6|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 2.44e-04 | 182 | 30 | 3 | 7b24a4f712e1ae1525e8f1c8ec4e1fc43489cbee | |
| ToppCell | droplet-Limb_Muscle-nan-21m-Macroglial-nan|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.44e-04 | 182 | 30 | 3 | a512863304fad80acaab60a8c6107eb7c9cbac99 | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_1|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.48e-04 | 183 | 30 | 3 | ff6dde877659cde9daa3263db0932c9c9ef1adac | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_1|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.52e-04 | 184 | 30 | 3 | cdf6f1c6cce97a7effa0c55959652e2c0b6992b3 | |
| ToppCell | LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.52e-04 | 184 | 30 | 3 | 42ce855b4f8475a8298192feec785bdc69bc5bb0 | |
| ToppCell | PCW_13-14-Neuronal|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 2.52e-04 | 184 | 30 | 3 | 65cf3460125e3dbc34978957bc138a449f71f7df | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_1-AT1-AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.56e-04 | 185 | 30 | 3 | 3bef59cc0aa939d2a7e52f0f6c61bc00528fe50b | |
| ToppCell | LPS_only-Epithelial_alveolar-AT_1-AT1|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.56e-04 | 185 | 30 | 3 | 0c247a3f394c42e2a6f67fee3d9cf33096fecd13 | |
| ToppCell | Control-Epithelial_alveolar-AT_2-Differentiating_AT2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.56e-04 | 185 | 30 | 3 | 0d2add28ac1f4fa6de7699be009bf8391badaf4c | |
| ToppCell | Control-Epithelial_alveolar|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.56e-04 | 185 | 30 | 3 | 3937e026add96a396122139daf8011cfbc60e75c | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.56e-04 | 185 | 30 | 3 | c82eab551f65ecebe6db908eda9f9eb3414693c7 | |
| ToppCell | LPS_only-Epithelial_alveolar|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.60e-04 | 186 | 30 | 3 | e0a2ea4b46af742bc7c9b2072bb85e27d5c92712 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.60e-04 | 186 | 30 | 3 | f0c8de4f6ae9047b9108a47a2af8c5f42bc103b0 | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.60e-04 | 186 | 30 | 3 | 4e94158db52df41d71e67b02b9895a358eebee0f | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.60e-04 | 186 | 30 | 3 | 3aebe163799109ffc67e4e10ee47c2dd0886a92c | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.64e-04 | 187 | 30 | 3 | 58d48128547ee3513d0bf7f78e61b76b1c472ca9 | |
| ToppCell | LPS_only-Epithelial_alveolar-AT_1|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.64e-04 | 187 | 30 | 3 | ff26a533d310126521efe1d05cf8b9d32e524550 | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.64e-04 | 187 | 30 | 3 | 201ff693e4756ee3e44762885b3a303a77eb535b | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.68e-04 | 188 | 30 | 3 | 6164d467b612767ceba15de34176bcc8e8c36ab8 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.68e-04 | 188 | 30 | 3 | 43a0508d2524a5b310e89e9422843dcaab999bc3 | |
| ToppCell | PCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.72e-04 | 189 | 30 | 3 | 7659c7bbd58ee959a159294fb8d17317bbcc5681 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.72e-04 | 189 | 30 | 3 | 7fbe855bfdb47d35e040b04a80fe4b729a3764e8 | |
| ToppCell | RA-10._Endothelium_II|World / Chamber and Cluster_Paper | 2.72e-04 | 189 | 30 | 3 | 75c248b9de5e2fb7a0baa8cdbab516e575cc4394 | |
| ToppCell | RA-10._Endothelium_II|RA / Chamber and Cluster_Paper | 2.72e-04 | 189 | 30 | 3 | c81787a8c662db5d7814c583dd64562857629e81 | |
| ToppCell | mild-Myeloid-Immature_Neutrophils_1|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 2.72e-04 | 189 | 30 | 3 | 94dd5d4d815449feff7ce157fe7f8234f7c81422 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.72e-04 | 189 | 30 | 3 | 06b35abecd29f902cf251fcc1f6ad33db7ab08a2 | |
| ToppCell | PCW_07-8.5-Epithelial-Epithelial_airway-epi_intermediate_(1)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.77e-04 | 190 | 30 | 3 | c95032bb3ee2b3d40fdf48016acb46d6f78a48a6 | |
| ToppCell | PCW_07-8.5-Epithelial-Epithelial_alveolar-distal-epi_SOX9^high_Etv5^high_distal_(10)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.77e-04 | 190 | 30 | 3 | 625c08a0e5227efc46daa512fd579c3938ff76c7 | |
| ToppCell | COVID-19-Heart-T_cell|Heart / Disease (COVID-19 only), tissue and cell type | 2.77e-04 | 190 | 30 | 3 | e6c3a6e01fef6c5b49f72661d4fb0414ba9046bf | |
| ToppCell | PCW_07-8.5-Epithelial-Epithelial_proliferating-epi_proliferating2_(13)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.85e-04 | 192 | 30 | 3 | 25378b5e4b0cea8415ff125783511fc25a56fc00 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.85e-04 | 192 | 30 | 3 | b54b0d5b88139905521c8d5d58332e89c08d589c | |
| ToppCell | PCW_07-8.5-Epithelial-Epithelial_alveolar-distal|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.85e-04 | 192 | 30 | 3 | b7c01e12b3e9be960a741b08835f1dfff65d0d47 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.85e-04 | 192 | 30 | 3 | bfab13793e54de2550ee171397f7ece0625cdb4a | |
| ToppCell | PCW_07-8.5-Epithelial-Epithelial_proliferating|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.85e-04 | 192 | 30 | 3 | 1aa5e4d9b32013a3f272561dcb8377f6805706df | |
| ToppCell | human_hepatoblastoma-Tumor_cells|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells) | 2.90e-04 | 193 | 30 | 3 | 503a979328c68b096680b71359a26f02fafdff35 | |
| ToppCell | control-Myeloid-Immature_Neutrophils_2|control / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 2.90e-04 | 193 | 30 | 3 | 33349830e9eba506470ad3661fad5e5a283d20ca | |
| ToppCell | droplet-Kidney-KIDNEY-1m|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.94e-04 | 194 | 30 | 3 | 837cee7e6147d92a2f4b86f1ed761a9bfe65b61d | |
| ToppCell | PCW_07-8.5-Epithelial|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.94e-04 | 194 | 30 | 3 | f63ceedb88a9abc8644ee94adfd541e7817c1e3a | |
| ToppCell | Tracheal-10x5prime-Stromal-Schwann|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 3.03e-04 | 196 | 30 | 3 | b6226163d9fc93ecfff2115bb74408303a000490 | |
| ToppCell | 3'-GW_trimst-2-SmallIntestine-Neuronal|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.03e-04 | 196 | 30 | 3 | eea354bdaf4c558df6a94ec4f2f817f7073821d9 | |
| ToppCell | Bronchial-10x5prime-Epithelial-Epi_alveolar-Dividing_AT2|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 3.08e-04 | 197 | 30 | 3 | 49689a03ab31e53386dbe15c77c09ca3a14ebf4e | |
| ToppCell | mild-Myeloid-Immature_Neutrophils_2|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 3.08e-04 | 197 | 30 | 3 | bd9d57e0c873f6526dca322f4dad8e6bd692586c | |
| ToppCell | LPS_IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 3.12e-04 | 198 | 30 | 3 | b598ab958e31f1e98bd06dc0097b58ac3a3f90a3 | |
| ToppCell | LPS_IL1RA-Epithelial_alveolar-AT_1-2_Progenitor-Progenitor_AT1-AT2|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 3.12e-04 | 198 | 30 | 3 | 8d9858dcb21f20d0c040b22a2cae543eaebd54bc | |
| ToppCell | Control_saline-Epithelial_alveolar-AT_1-Differentiating_AT1|Control_saline / Treatment groups by lineage, cell group, cell type | 3.12e-04 | 198 | 30 | 3 | 85f424cd9bb3117c9e322031024aabb87696ce47 | |
| ToppCell | 5'-GW_trimst-2-SmallIntestine-Neuronal|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.12e-04 | 198 | 30 | 3 | 6e314dc820db9c53fe7fc7c96bed4d7d9a325160 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.17e-04 | 199 | 30 | 3 | 8bf8d7cd774479f065bbbbcb5a4bd1aa91aa0d85 | |
| ToppCell | LPS_IL1RA-Epithelial_alveolar-AT_1|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 3.17e-04 | 199 | 30 | 3 | a270630626df614f8605abddb7dee7c4d74f6149 | |
| ToppCell | Tracheal-10x3prime_v2-Stromal-Schwann|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 3.17e-04 | 199 | 30 | 3 | 8dc65662c3ca1db2ba0091332f0658abc0afc5de | |
| ToppCell | LPS_anti-TNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 3.17e-04 | 199 | 30 | 3 | d43c605a4ff221cf78d91678c15d2ad20f831c7f | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.17e-04 | 199 | 30 | 3 | 0c060ef64341659f4b1247d0264ac12e53a7e12e | |
| ToppCell | Tracheal-10x3prime_v2-Stromal-Schwann-Schwann_nonmyelinating|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 3.17e-04 | 199 | 30 | 3 | a92718a3f1153b8d2196fd343ed5bc0ebc98cad7 | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Neuronal|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.17e-04 | 199 | 30 | 3 | 5f350d9c7da9ac111bf22623dd4fed7f7983c9fc | |
| ToppCell | Macroglial-Oligodendrocytes|Macroglial / cells hierarchy compared to all cells using T-Statistic | 3.22e-04 | 200 | 30 | 3 | 4dbac2f2587e87ca5a0622f50439bb5447e93c7f | |
| ToppCell | Macroglial-Oligodendrocytes-OPALIN---|Macroglial / cells hierarchy compared to all cells using T-Statistic | 3.22e-04 | 200 | 30 | 3 | 1314664c1721e9ecb1e2c3482a039044b0fe50a9 | |
| ToppCell | LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_only / Treatment groups by lineage, cell group, cell type | 3.22e-04 | 200 | 30 | 3 | 2dadf317a42a7e27cc1fac74f91b806c93a57108 | |
| ToppCell | Neuronal-Excitatory-eC(RORB)-eC_2-C1R-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 3.22e-04 | 200 | 30 | 3 | 891a80cbde575f81f3466217175f41e1d4f66d5e | |
| ToppCell | Macroglial-Oligodendrocytes-OPALIN-|Macroglial / cells hierarchy compared to all cells using T-Statistic | 3.22e-04 | 200 | 30 | 3 | 8b229f095fc113aecfc94b64862a9e0fdcc363ce | |
| ToppCell | LPS_IL1RA_TNF-Epithelial_alveolar-AT_1-Differentiating_AT1|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 3.22e-04 | 200 | 30 | 3 | ddfb1f006365bf16203ee49f20200f68220cc288 | |
| ToppCell | Macroglial-Oligodendrocytes-OPALIN----L1-6|Macroglial / cells hierarchy compared to all cells using T-Statistic | 3.22e-04 | 200 | 30 | 3 | 272909f4354f3ae22e2b2f8f35970e6b0e92cfe2 | |
| Drug | Salisorosides Rosavin | 3.43e-08 | 71 | 30 | 5 | CID003340349 | |
| Drug | ajm | 1.14e-06 | 16 | 30 | 3 | CID006323214 | |
| Drug | UCS15A | 2.70e-06 | 21 | 30 | 3 | CID005311041 | |
| Drug | AC1L9JC0 | 3.59e-06 | 23 | 30 | 3 | CID000446228 | |
| Drug | bosentan | 1.11e-05 | 106 | 30 | 4 | CID000104865 | |
| Drug | androstan-3-ol | 2.51e-05 | 6 | 30 | 2 | ctd:C000658 | |
| Drug | funiferine N-oxide | 3.65e-05 | 49 | 30 | 3 | CID000191631 | |
| Drug | nNOS inhibitor I | 4.12e-05 | 51 | 30 | 3 | CID000656911 | |
| Drug | 2,3,5,6-tetrafluoro-4-methylbenzyl (Z)-(1RS)-cis-3-(2-chloro-3,3,3-trifluoroprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate | 4.68e-05 | 8 | 30 | 2 | ctd:C489827 | |
| Drug | 1,1,1-trichloroethane | 5.06e-05 | 156 | 30 | 4 | CID000006278 | |
| Drug | p-acetaminobenzaldehyde thiosemicarbazone | 6.38e-05 | 59 | 30 | 3 | CID002733749 | |
| Drug | TEMPO | 7.06e-05 | 61 | 30 | 3 | CID002724126 | |
| Drug | alpha-CaM | 7.41e-05 | 62 | 30 | 3 | CID000196705 | |
| Drug | AC1MM84E | 8.93e-05 | 66 | 30 | 3 | CID003256856 | |
| Drug | AC1MMZLG | 9.34e-05 | 67 | 30 | 3 | CID003269220 | |
| Disease | MASA syndrome (implicated_via_orthology) | 1.95e-05 | 7 | 29 | 2 | DOID:0060246 (implicated_via_orthology) | |
| Disease | esophageal carcinoma, gastric carcinoma | 1.26e-04 | 17 | 29 | 2 | EFO_0000178, EFO_0002916 | |
| Disease | pyruvate measurement | 1.32e-04 | 268 | 29 | 4 | EFO_0010117 | |
| Disease | progression free survival, ovarian serous carcinoma | 2.13e-04 | 22 | 29 | 2 | EFO_0004920, EFO_1001516 | |
| Disease | Global developmental delay | 3.00e-04 | 133 | 29 | 3 | C0557874 | |
| Disease | cerebrospinal fluid clusterin measurement | 5.44e-04 | 35 | 29 | 2 | EFO_0007657 | |
| Disease | trauma exposure measurement | 6.36e-04 | 172 | 29 | 3 | EFO_0010703 | |
| Disease | macrophage migration inhibitory factor measurement | 8.21e-04 | 43 | 29 | 2 | EFO_0008221 | |
| Disease | childhood trauma measurement, smoking behaviour measurement | 8.99e-04 | 45 | 29 | 2 | EFO_0005671, EFO_0007979 | |
| Disease | Intellectual Disability | 9.14e-04 | 447 | 29 | 4 | C3714756 | |
| Disease | alcohol consumption measurement | 1.13e-03 | 1242 | 29 | 6 | EFO_0007878 | |
| Disease | body weight | 1.23e-03 | 1261 | 29 | 6 | EFO_0004338 | |
| Disease | response to cranial radiation therapy, short-term memory | 1.59e-03 | 60 | 29 | 2 | EFO_0004335, EFO_0010950 | |
| Disease | cognitive function measurement | 2.36e-03 | 1434 | 29 | 6 | EFO_0008354 | |
| Disease | initial pursuit acceleration | 3.31e-03 | 87 | 29 | 2 | EFO_0008434 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| AMEMLQKVKMMVVRV | 2926 | Q86UQ4 | |
| MLMMMTYSMVPIRVM | 111 | Q6ZMI3 | |
| KMNKMMMSEEQMKLP | 26 | P61578 | |
| MVRRLKMVVKTFMDM | 31 | Q9NTI5 | |
| CNVQAMEEMMMEMKY | 246 | Q9UGN5 | |
| MEEMMMEMKYNTKKA | 251 | Q9UGN5 | |
| LKKQMEVMEMEVMEA | 1336 | Q92614 | |
| MMLEQTRKEIVMAMM | 701 | P16499 | |
| SMYMKIIMPMVMHTE | 691 | Q9Y4C0 | |
| EQRMMIRELMDAQMK | 146 | O75469 | |
| MRGMMAKQEGMEMKL | 181 | O75330 | |
| QQMMMMLMMQQDPKS | 1031 | Q14686 | |
| AALEMMSQAMIRGMM | 236 | Q8N7H5 | |
| IIVLAKNMCMIMMEM | 701 | Q9UI47 | |
| KNMCMIMMEMTDFTR | 706 | Q9UI47 | |
| IIVLAKQMCMIMMEM | 711 | P26232 | |
| KQMCMIMMEMTDFTR | 716 | P26232 | |
| AKQMCMIMMEMTDFT | 716 | P35221 | |
| MEMERMMQAHRQMDP | 706 | Q86UU0 | |
| FGETMEMMDRMKDME | 1116 | Q13751 | |
| KMTLIPMNMMQVMSE | 1091 | Q5VU65 | |
| RMLIEMQSAMKTMMN | 186 | Q14995 | |
| EMVDMMNNRFRKDMM | 151 | Q9Y5J1 | |
| MVKMNVRVMSAILME | 211 | O75674 | |
| KCQMMEERANLMHMM | 106 | Q96T51 | |
| GMMMSIATKIAMQMT | 586 | Q7Z3Z4 | |
| EKMTMMMKILIMFAL | 6 | Q13103 | |
| MQQMYDMIMQHKRAM | 451 | Q8IWZ8 | |
| KSIVTMLMLMLLMMF | 536 | Q8TCJ2 | |
| IGKMMIDMMYFVIIM | 1026 | Q9HCF6 | |
| QLMMMVKEKMITIEE | 191 | O94885 | |
| IVIMMLICLNMVTMM | 1526 | Q9UQD0 | |
| VMMIGKMMIDMLYFV | 956 | Q7Z4N2 | |
| QDMMSNPDLMRHMIM | 206 | Q9NRR5 |